Neuropace Earnings Estimate

NPCE Stock  USD 15.35  0.26  1.67%   
By analyzing Neuropace's earnings estimates, investors can diagnose different trends across Neuropace's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Neuropace is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Neuropace is projected to generate -0.173225 in earnings per share on the 31st of December 2026. Neuropace earnings estimates show analyst consensus about projected Neuropace EPS (Earning Per Share). It derives the highest and the lowest estimates based on Neuropace's historical volatility. Many public companies, such as Neuropace, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Neuropace's earnings estimates, investors can diagnose different trends across Neuropace's analyst sentiment over time as well as compare current estimates against different timeframes. As of January 29, 2026, Gross Profit is expected to decline to about 42.1 M. In addition to that, Pretax Profit Margin is expected to decline to -0.32Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.

Neuropace Earnings per Share Projection vs Actual

About Neuropace Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Neuropace earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Neuropace estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Neuropace fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-477.9 M-501.7 M
Retained Earnings Total Equity-423.8 M-445 M
Earnings Yield(0.10)(0.10)
Price Earnings Ratio(10.81)(11.35)
Price Earnings To Growth Ratio 0.52  0.36 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuropace. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Will Health Care Equipment & Supplies sector continue expanding? Could Neuropace diversify its offerings? Factors like these will boost the valuation of Neuropace. Anticipated expansion of Neuropace directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neuropace data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.75)
Revenue Per Share
2.978
Quarterly Revenue Growth
0.299
Return On Assets
(0.11)
Return On Equity
(1.69)
Understanding Neuropace requires distinguishing between market price and book value, where the latter reflects Neuropace's accounting equity. The concept of intrinsic value—what Neuropace's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neuropace's price substantially above or below its fundamental value.
It's important to distinguish between Neuropace's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neuropace should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neuropace's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.